Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066063 · ClinicalTrials.gov registry record
A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming
A clinical trial of Amblyopia and Ocular Motility Disorders, sponsored by Barron Associates.
- Completed
- Registry status
- 92
- Enrollment target
- 1
- Study location
NCT03066063: Completed study of Amblyopia and Ocular Motility Disorders, sponsored by Barron Associates.
NCT03066063 is a study of Amblyopia and Ocular Motility Disorders that has completed, run by Barron Associates. The registered enrollment target is 92 participants, below the 162-participant average among 24 other Amblyopia trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03066063, a study of Amblyopia and Ocular Motility Disorders, has completed, sponsored by Barron Associates.
- COMPLETED
- Registry status
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The research team will execute two concurrent studies within a common framework. The first will compare iCare to standard of care occlusion therapy (patching) for amblyopia in patients ages 4 to 18 (inclusive). The second will compare iCare to a standard of care for home-based CI therapy (pencil pushups) for convergence insufficiency patients ages 8 to 18 (inclusive). In the context of this study, the term iCare refers to either the amblyopia or CI video game module as appropriate for the respective study group.
Primary Outcome
Pre- to post-intervention change in best-corrected vision measured using a logMAR (Logarithm of the Minimum Angle of Resolution) chart, which consists of rows of letters of different sizes. The scale ranges from -0.3 (approximately 20/10 vision on the Snellen chart) to 1 (approximately 20/200 vision). Lower scores indicate better vision.
Conditions Studied
Interventions
- DEVICE iCare
- BEHAVIORAL Amblyopia standard of Care
- BEHAVIORAL CI standard of Care
Study Locations (1)
Tennessee
- Southern College of Optometry - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-05-07 |
| Est. Completion | 2022-02-28 |
What the finished NCT03066063 record still lists
NCT03066063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 162-participant average among 24 other Amblyopia trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Amblyopia appearing as the primary indexed condition, and to 3 interventions - of which iCare is the first listed.
NCT03066063 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03066063 about?
NCT03066063 is a clinical study titled "A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming". The research team will execute two concurrent studies within a common framework. The first will compare iCare to standard of care occlusion therapy (patching) for amblyopia in patients ages 4 to 18 (inclusive). The second will compare iCare to a standard of care for home-based CI therapy (pencil pus...
What is the current status of trial NCT03066063?
This trial is currently completed. The enrollment target is 92 participants. The study started on 2019-05-07. Estimated completion is 2022-02-28.
What conditions does trial NCT03066063 study?
This clinical trial studies the following conditions: Amblyopia, Ocular Motility Disorders.
What interventions are being tested in trial NCT03066063?
The interventions under investigation include: iCare (DEVICE), Amblyopia standard of Care (BEHAVIORAL), CI standard of Care (BEHAVIORAL).
Who is sponsoring clinical trial NCT03066063?
This trial is sponsored by Barron Associates, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03066063 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amblyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03066063's enrollment target sits among peer trials
92 15th of 24 higher than 10 of 24 other Amblyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amblyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Noninvasive Brain Stimulation in Adult Amblyopia
RECRUITING · NA
-
OCT Eccentric Fixation and Amblyopia in Children
RECRUITING · NA
-
Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy
RECRUITING
-
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI